Last reviewed · How we verify
Prometa
At a glance
| Generic name | Prometa |
|---|---|
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately. Administration of folic acid alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B 12 is deficient. Precautions Folic acid in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission
Common side effects
- Nausea
- Gastrointestinal disturbances
- Diarrhea
- Constipation
- Anorexia
- Gastrointestinal intolerance
Serious adverse events
- Allergic sensitizations
- Allergic reactions
- Idiosyncratic reactions
Key clinical trials
- The Women's Screening and Self-Testing Program (PROMETA) Study (NA)
- Prometa Protocol for Alcohol Dependence (PHASE2, PHASE3)
- Prometa Pharmacotherapy for Methamphetamine Dependence (PHASE2, PHASE3)
- Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prometa CI brief — competitive landscape report
- Prometa updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI